To view or add a comment, sign in Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial To view or add a comment, sign in Retatrutide continues to redefine the future of obesity treatment
,
Ozempic (semaglutide) is a GLP-1 receptor agonist, meaning it imitates the functions of the intestinal hormone glucagon-like peptide-1 (GLP-1)
Liraglutide effects on upper Gastrointestinal investigations: implications prior to bariatric surgery
Reduction in Sleep Latency: Patients report significantly faster onset of sleep following treatment, attributed to the reduction in neural hyperexcitability and enhanced thalamocortical inhibition
however, the absolute risk differences were similar in trials for epilepsy and psychiatric indications